

BIOCATALYSIS FOR THE PHARMACEUTICAL INDUSTRY

Discovery, Development, and Manufacturing

Junhua (Alex) Tao

Elevance Renewable Sciences, USA

Guo-Qiang Lin

Shanghai Institute of Organic Chemistry, CAS, China

Andreas Liese

Hamburg University of Technology, Germany



John Wiley & Sons (Asia) Pte Ltd

BIOCATALYSIS FOR THE PHARMACEUTICAL INDUSTRY

BIOCATALYSIS FOR THE PHARMACEUTICAL INDUSTRY

Discovery, Development, and Manufacturing

Junhua (Alex) Tao

Elevance Renewable Sciences, USA

Guo-Qiang Lin

Shanghai Institute of Organic Chemistry, CAS, China

Andreas Liese

Hamburg University of Technology, Germany



John Wiley & Sons (Asia) Pte Ltd

Copyright © 2009

John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop, # 02-01,
Singapore 129809

Visit our Home Page on www.wiley.com

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as expressly permitted by law, without either the prior written permission of the Publisher, or authorization through payment of the appropriate photocopy fee to the Copyright Clearance Center. Requests for permission should be addressed to the Publisher, John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop, # 02-01, Singapore 129809, tel: 65-64632400, fax: 65-64646912, email: enquiry@wiley.com.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book. All trademarks referred to in the text of this publication are the property of their respective owners.

This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

Other Wiley Editorial Offices

John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA

Jossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USA

Wiley-VCH Verlag GmbH, Boschstrasse 12, D-69469 Weinheim, Germany

John Wiley & Sons Australia Ltd, 42 McDougall Street, Milton, Queensland 4064, Australia

John Wiley & Sons Canada Ltd, 5353 Dundas Street West, Suite 400, Toronto, ONT, M9B 6H8, Canada

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Library of Congress Cataloging-in-Publication Data

Tao, Junhua.

Biocatalysis for the pharmaceutical industry: discovery, development, and manufacturing/Junhua Tao, Guo-Qiang Lin, Andreas Liese.

p. cm.

Includes bibliographical references and index.

ISBN 978-0-470-82314-9 (cloth)

1. Pharmaceutical biotechnology. 2. Enzymes—Biotechnology. I. Lin, Guo-Qiang. II. Liese, A. (Andreas) III. Title.

RS380.T36 2009

615'.19—dc22

2008045613

ISBN 978-0-470-82314-9 (HB)

Typeset in 10/12pt Times by Thomson Digital, Noida, India.

Printed and bound in Singapore by Markono Print Media Pte Ltd, Singapore.

This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.

Contents

Preface	xi
1 Enzymes and Their Synthetic Applications: An Overview	1
1.1 Introduction	1
1.2 Enzyme Families	1
1.3 Enzyme Discovery and Optimization	2
1.4 Enzyme Production	3
1.5 Enzymes and Synthetic Applications	3
1.5.1 Ketoreductases (EC 1.1.1.2)	4
1.5.2 Enoate Reductases or Ene Reductases (EC 1.3.1.16)	4
1.5.3 Oxygenases (EC. xxxx)	5
1.5.4 Alcohol Oxidases (EC 1.1.3.X)	6
1.5.5 Peroxidases (EC 1.11.1.X)	7
1.5.6 Halogenases (EC. xxxx)	8
1.5.7 Nitrilases (EC 3.5.5.1)	9
1.5.8 Nitrile Hydratases (EC 4.2.1.84)	9
1.5.9 Epoxide Hydrolases (EC 3.3.2.X)	10
1.5.10 ω -Transaminases (EC 2.6.1.X)	10
1.5.11 Hydroxynitrile Lyases (EC 4.1.2.X)	10
1.5.12 Aldolases (EC. xxxx)	12
1.5.13 Glycosidases (EC. xxxx)	12
1.5.14 Glycosyltransferase (EC. xxxx)	14
1.6 Conclusions	15
2 Expression Hosts for Enzyme Discovery and Production	21
2.1 Introduction	21
2.2 How to Choose an Expression System	22
2.3 Prokaryotic Expression Systems	24
2.3.1 Posttranslational Modification in Prokaryotes	25
2.3.2 <i>Escherichia coli</i>	25
2.3.3 <i>Bacilli</i>	26
2.3.4 <i>Pseudomonas fluorescens</i>	27
2.3.5 Other Prokaryotic Expression Systems	28

2.4	Eukaryotic Expression Systems	29
2.4.1	Yeast	29
2.4.2	Filamentous Fungi	32
2.4.3	Insect/Baculovirus System	33
2.4.4	Mammalian Cell Cultures	34
2.4.5	Other Expression Systems	35
2.5	Cell-Free Expression Systems	36
2.6	Conclusions	37
3	Directed Enzyme Evolution and High-Throughput Screening	45
3.1	Introduction	45
3.2	Directed Evolution Library Creation Strategies	46
3.2.1	Random and Semi-Rational Mutagenesis	47
3.2.2	Gene Shuffling	48
3.3	Directed Evolution Library Screening/Selection Methods	52
3.3.1	<i>In Vivo</i> Methods: Genetic Complementation	52
3.3.2	<i>In Vivo</i> Methods: Chemical Complementation	53
3.3.3	<i>In Vivo</i> Methods: Surface Display	53
3.3.4	<i>In Vitro</i> Methods: Lysate Assay	55
3.3.5	<i>In Vitro</i> Methods: Ribosome Display	55
3.3.6	<i>In Vitro</i> Methods: <i>In Vitro</i> Compartmentalization	55
3.3.7	Equipment/Automation	56
3.4	Selected Industrial Examples	56
3.4.1	Activity	56
3.4.2	Thermostability	58
3.4.3	Substrate Specificity	58
3.4.4	Product Specificity	59
3.4.5	Enantioselectivity	59
3.5	Conclusions and Future Directions	60
4	Applications of Reaction Engineering to Industrial Biotransformations	65
4.1	Introduction	65
4.2	Metabolic Bioconversion	66
4.3	Enzymatic Biotransformations	67
4.3.1	Cofactor Regeneration	67
4.3.2	Racemic Mixtures	69
4.3.3	Equilibrium Conversion	72
4.3.4	By-Product Formation	76
4.3.5	Substrate Inhibition	79
4.3.6	Low Solubility	82
4.4	Conclusions	83
5	Chiral Synthesis of Pharmaceutical Intermediates Using Oxynitrilases	89
5.1	Introduction	89
5.2	HNL	89
5.2.1	The Natural Function and Distribution of HNLs	89

5.2.2	Classification of HNLs	91
5.2.3	New HNLs and High-Throughput Screening	93
5.3.	Reaction of HNLs	95
5.3.1	Reaction System	95
5.3.2	Immobilization of Enzyme	97
5.3.3	Continuous Reactors	98
5.3.4	Henry Reaction	98
5.4	Transformation of Cyanohydrins	99
5.4.1	Transformation of Hydroxyl Group	99
5.4.2	Transformation of Nitrile Group	100
5.4.3	Intramolecular Reaction	102
5.5	Summary	104
6	Expanding the Scope of Aldolases as Tools for Organic Synthesis	111
6.1	Directed Evolution and Rational Mutagenesis	111
6.2	Reaction Engineering	114
6.3	Broad Substrate Tolerance of Wild-Type Aldolases	116
6.4	Conclusions	118
7	Synthetic Applications of Ketoreductases and Alcohol Oxidases	121
7.1	Ketoreductases	121
7.1.1	Wild-Type Whole-Cell Biocatalysts	122
7.1.2	Recombinant Whole-Cell Biocatalysts Overexpressing Catalytic Enzymes	125
7.1.3	Isolated Enzyme	129
7.2	Alcohol Oxidases	142
7.2.1	Primary Alcohol Oxidases	142
7.2.2	Secondary Alcohol Oxidases	144
8	Applications of Nitrile Hydratases and Nitrilases	153
8.1	Introduction	153
8.2	NHase	153
8.2.1	New NHases	153
8.2.2	Applications	154
8.3	Nitrilase	163
8.3.1	New Nitrilases	163
8.3.2	Applications	167
8.4	Conclusions	178
9	Biosynthesis of Drug Metabolites	183
9.1	Introduction	183
9.2	Metabolite Synthesis Using Mammalian Bioreactors	184
9.2.1	Selection of <i>In Vitro</i> Systems	185
9.2.2	Reaction Condition Optimization	187
9.2.3	Large Scale Incubations	190

9.2.4	Examples with Mammalian Bioreactors	190
9.2.5	<i>In Vivo</i> Samples	192
9.3	Metabolite Synthesis Using Microbial Bioreactors	192
9.3.1	Microbial Bioreactors Used in Metabolite Structure Elucidation	193
9.3.2	Microbial Bioreactors Used in Synthesis of Key Metabolites	193
9.3.3	Strain Selection	194
9.3.4	Microbial Glycoside Conjugation	196
9.3.5	Large Scale Reactions	199
9.3.6	Examples for Metabolite Synthesis with a Microbial Bioreactor	200
9.4	Recombinant Enzyme Bioreactors	202
9.4.1	Advantages of Using CYP Enzymes for Producing Drug Metabolites	202
9.4.2	Human Cytochrome Biocatalysts	205
9.4.3	Microbial CYP Enzymes	206
9.5	Summary	207
10	Application of Whole-Cell Biotransformation in the Pharmaceutical Industry	213
10.1	Introduction	213
10.1.1	Whole-Cell Biotransformation Processes Used in Commercial Production of Pharmaceuticals	214
10.1.2	Application of Whole-Cell Biotransformation Process in the Synthesis of Chiral Pharmaceutical Intermediates	214
10.2	Disadvantages of Whole-Cell Process Compared with the Isolated Enzyme Process	217
10.2.1	Substrate Availability and Recovery of Products in Low Concentrations	217
10.2.2	Undesirable Side Reactions	217
10.2.3	Toxicity of Substrate and Product	217
10.3	Advantages of Whole-Cell Process Compared with the Isolated Enzyme Process	218
10.3.1	More Stable Sources than Isolated Enzymes	218
10.3.2	Regeneration of Cofactors and Multi-Enzymes Reactions	218
10.3.3	Diversity and Availability	218
10.3.4	Reactions with Non-Commercially Available Isolated Enzymes for Preparative Scale Synthesis	218
10.3.5	Cost Effectiveness and Ease of Operation	219
10.4	Approaches to Address the Disadvantages of Whole-Cell Biotransformation	220
10.4.1	Control of Substrate and Product Concentration by Absorbing Resins	220
10.4.2	Immobilized-Cell Technology	221
10.4.3	Aqueous–Organic Two-Phase System	222
10.4.4	Genetic Engineering Approaches	223
10.5	Conclusions	224

11 Combinatorial Biosynthesis of Pharmaceutical Natural Products	229
11.1 Introduction	229
11.2 Combinatorial Biosynthesis: The Natural Way for Structural Diversity	230
11.3 Examples of Combinatorial Biosynthesis of Pharmaceutical Natural Products	234
11.3.1 Erythromycin (Polyketide Biosynthesis)	234
11.3.2 Daptomycin (Nonribosomal Peptide Biosynthesis)	236
11.3.3 Patellamide (Ribosomal Peptide Biosynthesis)	239
11.4 Summary and Perspectives	240
12 Metabolic Engineering for the Development and Manufacturing of Pharmaceuticals	247
12.1 Introduction	247
12.2 Metabolic Engineering Tools	248
12.2.1 Tools for the Cellular Metabolic Network Analysis	248
12.2.2 Tools for Rational Genetic Modification	251
12.3 Metabolic Engineering for the Development and Production of Polyketide Pharmaceuticals	253
12.3.1 Biosynthesis of Polyketides	253
12.3.2 Metabolic Engineering for Improved Erythromycin Production	253
12.3.3 Metabolic Engineering for Overproduction of 6dEB in Heterologous Hosts	254
12.3.4 Metabolic Engineering of Other Polyketides	256
12.3.5 Development of Novel Polyketides for Drug Discovery	256
12.4 Metabolic Engineering for the Production of β -Lactam	257
12.5 Metabolic Engineering for Isoprenoid Production	258
12.5.1 Biosynthesis Pathway of Isoprenoids	259
12.5.2 Metabolic Engineering for Enhancing Precursor Supply for Isoprenoid Production	260
12.5.3 Metabolic Engineering for Artemisinine Development and Production	261
12.5.4 Metabolic Engineering for Carotenoid Production	262
12.5.5 Metabolic Engineering for Taxol Development and Production	262
12.6 Conclusions	265
13 Multimodular Synthases and Supporting Enzymes for Chemical Production	273
13.1 Introduction	273
13.2 Background	274
13.2.1 Multimodular Synthase Architecture	274
13.2.2 Natural Product Biosynthetic Cycle	276
13.3 Metabolic Engineering of Megasynthases	277
13.3.1 Daptomycin: Metabolic Engineering by Domain Swap	278
13.3.2 Avermectin: Metabolic Engineering by Directed Fermentation	281

13.4	Excised Domains for Chemical Transformations	284
13.4.1	Function of Individual Domains, Domain Autonomy	284
13.4.2	Cyclization	285
13.4.3	Halogenation	288
13.4.4	Heterocyclization/Aromatization	290
13.4.5	Methylation	292
13.4.6	Oxygenation	294
13.4.7	Glycosylation	295
13.5	Conclusions	299
14	Green Chemistry with Biocatalysis for Production of Pharmaceuticals	305
14.1	Introduction	305
14.2	Enzymatic Resolutions: Higher Yields, Less Waste	309
14.3	Bioreductions: Greener Ligands, Renewable Hydride Donors, No Metals	312
14.3.1	Enzymatic Oxidations: Clean, Highly Selective and Catalytic	314
14.4	C–C Bond Formations: Atom Efficiency at Its Best	316
14.5	Summary and Outlook	318
Index		323

Preface

Biocatalysis is evolving to be a transformational technology as a result of a confluence of factors, which include (1) large scale and ever increasingly cost-efficient DNA sequencing technologies; (2) exponential growth in GenBank; (3) powerful directed enzyme evolution and high-throughput screening technologies; (4) robust expression systems for enzyme production; (5) deep understanding of the logic of natural product biosynthesis; (6) industrial successes of metabolic engineering and pathway engineering.

Consequently, many successful stories and a number of reviews have been reported recently in developing biocatalysis for the pharmaceutical industry, across drug discovery, development, and manufacturing. The book is dedicated to these advances, and divided into four parts:

- Chapters 1–4 serve as an introduction to emerging biocatalysts, modern expression hosts, state of the art of directed evolution, high-throughput screening, and bioprocess engineering for industrial applications.
- Chapters 5–8 are directed to emerging enzymes, which include oxynitrilases, aldolases, ketoreductases, oxidases, nitrile hydratases, and nitrilases, and their recent applications especially in synthesis of chiral drugs and intermediates.
- Chapters 9 and 10 focus on synthesis of drug metabolites and intermediates catalyzed by P450s or whole cells.
- Chapters 11–13 are devoted to combinatorial biosynthesis, metabolic engineering, and autonomous enzymes for the synthesis and development of complex medicinal molecules.
- Chapter 14 discusses the recent impact of biocatalysis in green chemistry and chemical development.

Our main goal is to come up with a concise but comprehensive, practical but insightful book covering the topics discussed above. We hope you enjoy reading this book. Any suggestions and comments are welcome.

Junhua (Alex) Tao
Elevance Renewable Sciences, USA
Email: Junhua_tao@yahoo.com

Guo-Qiang Lin
Guo-Qiang Lin Shanghai Institute of Organic Chemistry, China
Email: lingq@mail.sioc.ac.cn

Andreas Liese
Hamburg University of Technology, Germany
Email: liese@tuhh.de

1

Enzymes and Their Synthetic Applications: An Overview

Junhua (Alex) Tao¹ and Jian-He Xu²

¹*Elevance Renewable Sciences, 175 E. Crossroads Parkway, Bolingbrook, IL 60440, USA*

²*East China University of Science and Technology (ECUST) 130 Meilong Road, Shanghai, 200237, PR China*

1.1 Introduction

Whole-cell biocatalysis has been exploited for thousands of years; for example, in preparing barley for beer brewing. While the chemical, economic and social advantages of biocatalysis over traditional chemical approaches were recognized a long time ago, their applications for the drug industry have been largely underexplored until the recent technological breakthroughs in large-scale DNA sequencing, robust protein expression systems, metabolic engineering and directed evolution. In this chapter, emphasis will be directed to the discussion of those isolated enzymes which are uniquely suited for the synthesis of small-molecule pharmaceutical ingredients.

1.2 Enzyme Families

Based on reactions they catalyze, enzymes can be broadly classified into six major categories (Table 1.1) [1]. It was estimated that about 60% of biotransformations currently rely on the use of hydrolases, followed by 20% of oxidoreductases [2]. On the other hand, some of the C–C bond-forming and oxygenation enzymes catalyze reactions with very high reaction efficiency and very low waste generation, underlining the potential of emerging enzymes.

Table 1.1 Enzyme classes

Enzyme class	Examples	Reaction catalyzed
Hydrolases	lipase, protease, esterase nitrilase, nitrile hydratase glycosidase, phosphatase	hydrolysis reactions in H ₂ O
Oxidoreductases	dehydrogenase, oxidase oxygenase, peroxidase	oxidation or reduction
Transferases	transaminase, glycosyltransferase transaldolase	transfer of a group from one molecule to another
Lyases	decarboxylase, dehydratase, deoxyribose-phosphate aldolase	nonhydrolytic bond cleavage
Isomerases	racemase, mutase	intramolecular rearrangement
Ligases	DNA ligase	bond formation requiring triphosphate

1.3 Enzyme Discovery and Optimization

Traditionally, enzymes are discovered through screening of environmental samples and culture enrichment. As a result of recent technological breakthroughs in large-scale DNA sequencing and high-throughput screening, both the metagenomic approach and sequence-based discovery have drastically shortened the cycle of enzyme discovery.

In the metagenomic approach, DNA was directly extracted from uncultured samples followed by cloning and expression [3]. For example, by combination of directed evolution with the metagenome approach, an α -amylase mutant with optimal activity at pH 4.5 and optimal thermostability at 105 °C was discovered for starch liquefaction and EtOH production [4].

Sequence-based discovery (genome hunting) is increasingly attractive, as the public sequence bank is growing rapidly. In this approach, known sequences encoding an enzyme of interest are used to search gene databases to uncover enzymes of homologous sequences. For example, using this method, a library of deoxyribose-phosphate aldolases (DERAs) were rapidly constructed and from them a novel DERA was identified to catalyze a sequential aldol reaction of a nonnative substrate with high throughput and excellent stereoselectivity for the synthesis of statin side chains [5].

Since most synthetic applications require enzymes catalyzing nonnatural substrates, their properties often have to be improved. One way to achieve this is to optimize reaction conditions such as pH, temperature, solvents, additives, etc. [6–9]. Another way is to modulate the substrates without compromising the synthetic efficiency of the overall reaction [10]. In most cases for commercial manufacturing, however, the protein sequences have to be altered to enhance reactivity, stereoselectivity and stability. It was estimated that over 30 commercial enzymes worldwide have been engineered for industrial applications [11]. Precise prediction of which amino acids to mutate is difficult to achieve. Since the mid 1990s, directed evolution

has been demonstrated to be a powerful and robust technology to improve the desired properties [12,13]. Among them, the error-prone PCR method is probably the most popular to create random mutants by changing polymerization reaction conditions [14]. Alternatively, recombination of homologous sequences or DNA-shuffling methods can be used to introduce mutants with improved properties [15]. The major challenge in directed evolution is not generation of mutant libraries; rather, it is the availability of high-throughput assays [16]. In most cases, it requires screening of tens of thousands of mutants, which is usually tedious and time consuming. As more and more protein structures are available from the protein database, focused directed evolution or semi-rational protein design is becoming more and more popular [17]. In this approach, the three-dimensional (3-D) structure of a suboptimal enzyme is constructed by a computer algorithm from a homologous enzyme with known 3-D structure. Docking studies are then applied to search potential 'hot spots', which are then swapped with other amino acids by site-saturation mutagenesis. In this way, there are generally less than a few thousand mutants to be screened, significantly shortening the cycle of enzyme development. The fact that most beneficial mutations are proved to be near the active site makes this approach even more attractive [18].

1.4 Enzyme Production

Although some enzymes are still extracted from animal or plant tissue, most of them are now produced from microorganisms by fermentation. Bacteria and fungi are the most popular hosts for producing industrial enzymes, due to easy handling and high productivity. They can also be readily genetically engineered to improve their performance; for example, by incorporating secretion systems to facilitate enzyme isolation and purification. Some of the most popular expression hosts are *Escherichia coli*, *Pichia pastoris*, *Pseudomonas fluorescens*, *Aspergillus* sp. and *Bacillus* sp. Mammalian or plant cells are used in special cases [19–21]. By regulation, the production host should have GRAS status (Generally Regarded as Safe Status).

In a typical enzyme production procedure, cells containing genes encoding desired enzymes are grown in an Erlenmeyer flask. At large scale, a computer-controlled fermenter or bioreactor is required to maintain an appropriate control of pH, O₂, NH₃ and CO₂ to maximize cell density. The cells are harvested by centrifugation in a batch or continuous fashion. Alternatively, they can be collected through membrane filtration devices. The cell membranes are then disrupted by an ultrasonicator or French press at small scale. At a scale of over 5–10 L, a homogenizer is usually used. After centrifugation to remove cell debris, the crude enzymes remain in the supernatant and can be concentrated through precipitation by adding either inorganic salts (e.g. ammonium sulfate) or organic solvents (e.g. acetone). The crude enzymes are then purified by dialysis or a variety of chromatographic methods. The dry powder is usually obtained after lyophilization under freeze-drying conditions [22,23].

1.5 Enzymes and Synthetic Applications

Historically, the most popular enzymes used for chemical synthesis are lipases, esterases, proteases, acylases and amidases, among others. Recently, a number of recombinant biocatalysts have been discovered and isolated, significantly expanding the toolbox for biotransformations. In this section, the focus will be on these new enzymes.

1.5.1 Ketoreductases (EC 1.1.1.2)

Ketoreductases (KREDs) catalyze the conversion of a wide range of ketones and some aldehydes to chiral alcohols regio- and stereo-selectively in the presence of NADH or NADPH (Figure 1.1) [24,25]. This powerful transformation has been demonstrated in a number of industrial transformations using either isolated enzymes or whole cells. The use of isolated enzymes is often preferred because of a higher volumetric productivity and the absence of side reactions. A key to its success is the availability of efficient and cost-effective cofactor regeneration methods by using a formate dehydrogenase to recycle NAD⁺ or a glucose dehydrogenase to recycle NADP⁺ (Figure 1.1) [26,27]. It shall be noted that some alcohol dehydrogenases are also able to catalyze the oxidation of alcohols to ketones or aldehydes [28].




Figure 1.1

1.5.2 Enoate Reductases or Ene Reductases (EC 1.3.1.16)

Enoate reductase (ER) catalyzes NAD(P)H-dependent reduction of carbon–carbon double bonds of nonactivated enoates, as well as of α,β -unsaturated aldehydes, ketones, nitros, and nitriles (Figure 1.2). For example, the ER from *Clostridium tyrobutyricum* shows high stereospecificity and regioselectivity and broad substrate specificity [29]. Alkanes with up to two chiral centers can be directly produced by asymmetric reduction of electron-deficient alkene enzymes from the ‘old yellow enzyme’ family at the expense of NAD(P)H. The cofactor can be regenerated *in vitro* using a formate dehydrogenase or glucose dehydrogenase. Alternatively, a whole-cell system can be used to co-express ERs with redox enzymes for NAD(P)H recycling [30].





Figure 1.2

1.5.3 Oxygenases (EC. xxxx)

Oxygenases catalyze direct incorporation of molecular oxygen into substrates to produce oxygenated molecules [31,32]. They are categorized as either monooxygenases (MOs) or dioxygenases, depending upon whether one or both atoms of dioxygen are inserted into a substrate. The metal-dependent MOs, such as P450s, catalyze a wide range of reactions via metal oxo species (e.g. hydroxylation of alkanes and aromatics; epoxidation of alkenes (Figure 1.3)), while flavin adenine dinucleotide (FAD)-dependent MOs are found to catalyze oxidation of heteroatoms (S, N, Se, P) and Baeyer–Villiger reactions via FAD-hydroperoxide (FAD-OOH) species (Figure 1.4).



Examples:






Figure 1.3

Simplified Mechanism (FAD-dependent MOs)

Figure 1.4

Dioxygenases usually contain a tightly bound iron atom and catalyze hydroperoxidation of allylic molecules or carboxylic acids, and dihydroxylation of aromatics (Figure 1.5) [33].

Currently, these oxygenation reactions are usually carried out in whole cells, the outcome of which is often unpredictable. The discovery of novel oxygenases and efficient hosts for protein expression remain keys to further expanding the applications of these enzymes in chemical synthesis and drug metabolism studies [34–37].


Figure 1.5

1.5.4 Alcohol Oxidases (EC 1.1.3.X)

Alcohol oxidases (AOs) catalyze oxidation of alcohols to aldehydes or ketones in the presence of molecular oxygen, with hydrogen peroxide being the usual by-product (Figure 1.6). Some of the most well-studied AOs are cholesterol oxidases, short-chain aliphatic alcohol oxidases, aromatic alcohol oxidases, pyranose oxidases, glycolate oxidases, glucose oxidases, galactose oxidases and nucleoside oxidases [38–40]. Cholesterol oxidases catalyze oxidation of allylic alcohol in the cholesterol scaffolds [41]. The regeneration of cofactor FAD is relatively easier, as it is tightly bound. Although these enzymes use oxygen, they can also be deactivated by oxygen or the hydrogen peroxide by-product. It is to be noted that peroxidases and chloroperoxidases can also catalyze the oxidation of alcohols using hydrogen peroxide (H_2O_2).




Figure 1.6

1.5.5 Peroxidases (EC 1.11.1.X)

Peroxidases utilize H_2O_2 as the oxidant (Figure 1.7). The active site of peroxidases may involve a heme unit (horseradish peroxidase), selenium (glutathione peroxidase), vanadium (bromo-peroxidase) and manganese (manganese peroxidase). These enzymes catalyze a wide range of oxidations, including hydroxylation of arenes, oligomerization of phenols and aromatic amines, epoxidation and halogenation of olefins, oxygenation of heteroatoms and reduction of hydroperoxides [42–44].




Figure 1.7

1.5.6 Halogenases (EC. xxxx)

Halogenases catalyze regio- and stereo-selective halogenation (Figure 1.8) [45,46]. For electron-rich substrates, nature often uses flavin-dependent halogenases for chlorination, bromination or iodination via FADH-OX (X = halide) as the halogenation agent (Figure 1.9). For electron-deficient molecules such as alkanes, mononuclear iron halogenases are utilized through a radical mechanism (Figure 1.9). Fluorinases adopt an S_N2 nucleophilic substitution




Figure 1.8

Cofactors and Oxidants of Halogenating Enzymes





Figure 1.9

mechanism in the presence of F^- to introduce a fluorine atom [47]. While it is still in its infancy, the use of enzymatic halogenation has shown great promise, especially in whole-cell systems (Figure 1.9). For example, tryptophan 7-halogenase was able to catalyze regioselective halogenation of a wide range of indole derivatives and aromatic heterocycles [48]. It is to be noted that halogenation can also be catalyzed by haloperoxidases, which often gives poor regio- and stereo-selectivity, since the activated halogen source, (e.g. hypohalous acids) is freely diffusible within and away from enzymes (Figure 1.8) [49].

1.5.7 Nitrilases (EC 3.5.5.1)

Nitrilases convert nitriles to the corresponding carboxylic acids and NH_3 through a cysteine residue in the active site [50]. Because of their high enantio- and regio-selectivity, nitrilases are attractive as 'green' catalysts for the synthesis of a variety of carboxylic acids and derivatives (Figure 1.10) [51,52]. Recently, a number of recombinant nitrilases have been cloned and characterized heterologously for synthetic applications [50,53,54].

Mechanism:



R = aryl, alkenyl, alkyl

Product Examples:





Figure 1.10

1.5.8 Nitrile Hydratases (EC 4.2.1.84)

Nitrile hydratase (NHase) catalyzes the hydration of nitriles to amides (Figure 1.11) and has been used for production of acrylamide and nicotinamide at large scale. NHases are roughly

Mechanism:



R = aryl, alkenyl, alkyl

Product Examples:




Figure 1.11

classified into iron and cobalt types according to the metal involved in the active site [55,56]. Recent elucidation of the catalytic mechanism and characterization of a number of NHases have led to a wide range of applications in both biotransformation and bioremediation [53].

1.5.9 Epoxide Hydrolases (EC 3.3.2.X)

Epoxide hydrolases (EHs) catalyze the hydrolysis of a wide range of epoxides (Figure 1.12). They are cofactor independent and robust for the synthesis of enantiopure epoxides, diols and their derivatives [57–59]. There are over 100 epoxide hydrolase gene sequences, and the X-ray structures are available for fungal, bacterial and mammalian epoxide hydrolases [60]. Heterologous expression in *E. coli* and other hosts has also been successful. In addition, several efficient high-throughput screening methods have been developed, allowing the improvement of EHs through site-directed mutagenesis and directed evolution [61,62]. EHs also play important roles in the detoxification of genotoxic compounds and drug metabolism [63].




Figure 1.12

1.5.10 ω -Transaminases (EC 2.6.1.X)

ω -Transaminases catalyze the conversion of a ketone group to an amine in the presence of the cofactor pyridoxal-5'-phosphate (PLP), which is tightly bound to the active site. The catalysis starts with the formation of an imine between the cofactor and an amine donor (Figure 1.13) [64]. Since this is a one-step method to prepare (*R*)- or (*S*)-amines from ketones, it has huge potential (Figure 1.14) [65,66]. For example, a high-throughput biocatalytic process to (*S*)-methoxyisopropylamine, a moiety common to the two important chloroacetamide herbicides metolachlor and dimethenamid, has been reported by enzymatic transamination of methoxyacetone using isopropylamine as the donor [67].

1.5.11 Hydroxynitrile Lyases (EC 4.1.2.X)

Hydroxynitrile lyases (HNLs or oxynitrilases) catalyze C–C bond-forming reactions between an aldehyde or ketone and cyanide to form enantiopure cyanohydrins (Figure 1.15), which are versatile building blocks for the chiral synthesis of amino acids, hydroxy ketones, hydroxy acids, amines and so on [68]. Screening of natural sources has led to the discovery of both





Figure 1.13

Examples:

Other product examples:




Figure 1.14


 R = aromatic, alkyl, heterocyclic

Figure 1.15

(*R*)- and (*S*)-selective HNLs. A number of recombinant HNLs have also been expressed in *E. coli*, *Saccharomyces cerevisiae*, and *Pichia pastoris*. Recently, protein engineering has been successfully applied to the development of a tailor-made HNL for large-scale production of specific cyanohydrins [69,70].

1.5.12 Aldolases (EC. xxxx)

Aldolases catalyze asymmetric aldol reactions via either Schiff base formation (type I aldolase) or activation by Zn^{2+} (type II aldolase) (Figure 1.16). The most common natural donors of aldoalses are dihydroxyacetone phosphate (DHAP), pyruvate/phosphoenolpyruvate (PEP), acetaldehyde and glycine (Figure 1.17) [71]. When acetaldehyde is used as the donor, 2-deoxyribose-5-phosphate aldolases (DERAs) are able to catalyze a sequential aldol reaction to form 2,4-didexoyhexoses [72,73]. Aldolases have been used to synthesize a variety of carbohydrates and derivatives, such as azasugars, cyclitols and densely functionalized chiral linear or cyclic molecules [74,75].







Figure 1.16

1.5.13 Glycosidases (EC. xxxx)

Glycosidases catalyze the hydrolysis of glycosidic linkages via an oxonium intermediate or transition state similarly to acid-catalyzed hydrolysis of glycosides under either a retention of the configuration at the anomeric center (Mechanism, Figure 1.18) or less common inversion. The oxonium is presumably stabilized by a carboxylate group such as glutamic acid, a common structural motif in the active site of glycosidases [76]. Glycosidase-catalyzed synthesis of glycosides can be achieved under either equilibrium-controlled conditions or kinetic-controlled conditions [77–79]. In the former case, the reaction is established to shift the equilibrium toward a product; for example, by adding organic solvents. In the latter case, activated glycosyl donors are


Examples:**Figure 1.17****Mechanism:****Examples:****Figure 1.18**

used, which include di- or oligo-saccharides, aryl glycosides, glycosyl fluorides and so on [80]. Owing to greater promiscuity toward donors and wide availability, these enzymes were found to have a wide range of applications in preparation of carbohydrates and derivatives [81–83].

1.5.14 Glycosyltransferase (EC. xxxx)

Glycosyltransferases (Gtfs) accept activated sugars such as uridine diphosphate (UDP) nucleotide sugars or glycosyl phosphates as monosaccharide donors under either a retention or inversion of the configuration at the anomeric center (Mechanism, Figure 1.19; only inversion scenario shown). Recently, a number of Gtfs have been discovered to be quite promiscuous, and used to synthesize many oligosaccharides, their derivatives or glycosylated natural products, which are otherwise difficult to obtain [84–87]. For large-scale applications, the main issue to be overcome is to recycle released nucleotide monophosphate (NMP) or nucleotide diphosphate (NDP), which are expensive. Several methods have been reported [88,89], and one utilizes sugar nucleotide pyrophosphorylase, which transfers the sugar moiety of a sugar phosphate to a free uridine triphosphate (UTP) to regenerate the desired UTP-sugar (Figure 1.19) [90]. The availability of a wide range of Gtfs and sugar donors also provides a general strategy to synthesize glycosylated molecules *in vivo* through pathway engineering and combinatorial biosynthesis. For example, novel macrocyclic polyketides have been produced by applying a promiscuous Gtf from picromycin biosynthesis, which accepts a wide range of sugar donors (Figure 1.19) [91,92].

Mechanism (inversion scenario):



LG = leaving group: phosphate, UTP, TDP, etc.
NuH = nucleophile: alcohol, sulfide, amine, etc.

Examples:




Figure 1.19

1.6 Conclusions

Biocatalysis has been practiced historically mostly by whole-cell systems, which limits its applications due to low throughput and complex *in vivo* pathways. As a result of recent advances in genomics and high-throughput screening, more and more diverse recombinant enzymes are available in catalogs. Subsequently, a number of them have been successfully applied to the commercial production of nonnatural molecules. More recently, biocatalysis is emerging to be one of the greenest technologies for chemical synthesis [93,94]. Specifically, biocatalysis can prevent waste generation by using catalytic processes with high stereo- and region-selectivity, prevent or limit the use of hazardous organic reagents by using water as the green solvent, design processes with higher energy efficiency and safer chemistry by conducting reactions at room temperature under ambient atmosphere, and increase atom economy by avoiding extensive protection and deprotection to maximize the use of renewable feedstock designed for degradation.

Enzymes can catalyze transformations which are difficult to achieve by traditional chemical methods. To truly realize the promise of this emerging technology for the pharmaceutical industry, it is essential to integrate biocatalysis into drug discovery, development and manufacturing. For drug production, the key relies on integration of enzymatic transformations with modern chemical research and development at the retrosynthetic level to deliver efficient and practical synthetic sequences with fewer synthetic steps and significantly reduced waste streams [95,96].

References

- [1] Tipton, K. and Boyce, S. (2000) History of the enzyme nomenclature system. *Bioinformatics*, **16**, 34–40.
- [2] Straathof, A.J., Panke, S. and Schmid, A. (2002) The production of fine chemicals by biotransformations. *Current Opinion in Biotechnology*, **13**, 548–556.
- [3] Langer, M., Gabor, E.M., Liebeton, K. *et al.* (2006) Metagenomics: an inexhaustible access to nature's diversity. *Biotechnology Journal*, **1**, 815–821.
- [4] Mathur, E.J., Toledo, G., Green, B.D. *et al.* (2005) A biodiversity-based approach to development of performance enzymes: applied metagenomics and directed evolution. *Industrial Biotechnology*, **1**, 283–287.
- [5] Hu, S., Tao, J. and Xie, Z. Chemoenzymic synthesis of atorvastatin. WO2006134482.
- [6] Liu, Y.-Y., Xu, J.-H., Xu, Q.-G. and Hu, Y. (1999) Significant enhancement of lipase enantioselectivity toward (S)-ketoprofen ester at pH 2. *Biotechnology Letters*, **21**, 143–146.
- [7] Xu, T.-W., Xu, J.-H., Yu, W. and Zhong, J.-H. (2006) Investigating pH and Cu(II) effects on lipase activity and enantioselectivity via kinetic and spectroscopic methods. *Biotechnology Journal*, **1**, 1293–1301.
- [8] Liu, Y.-Y., Xu, J.-H. and Hu, Y. (2000) Enhancing effect of Tween-80 on lipase performance in enantioselective hydrolysis of ketoprofen ester. *Journal of Molecular Catalysis B: Enzymatic*, **10**, 523–529.
- [9] Gong, P.-F., Xu, J.-H., Tang, Y.-F. and Wu, H.-Y. (2003) Improved catalytic performance of *Bacillus megaterium* epoxide hydrolase in a medium containing Tween-80. *Biotechnology Progress*, **19**, 652–654.
- [10] Tao, J., Zhao, L. and Ran, N. (2007) Recent advances in developing chemoenzymatic processes for active pharmaceutical ingredients. *Organic Process Research Development*, **11**, 259–267.
- [11] Eggleston, G. and Vercellotti, J.R. (eds) (2007) *Industrial Applications of Enzymes on Carbohydrate-based Materials*, ACS Symposium Series 6, Oxford University Press.
- [12] Bloom, J.D., Meyer, M.M., Meinhold, P. *et al.* (2005) Evolving strategies for enzyme engineering. *Current Opinion in Structural Biology*, **15**, 447–452.
- [13] Reetz, M.T. (2007) Directed evolution of enzymes for asymmetric syntheses, in *Asymmetric Synthesis* (eds Christmann M. and Braese S.), Wiley–VCH, pp. 207–211.
- [14] Eggert, T., Jaeger, K.-E. and Reetz, M.T. (2004) Directed evolution of random mutagenesis: a critical evaluation, in *Enzyme Functionality* (ed. A. Svendsen), Marcel Dekker, Inc., New York, pp. 375–390.

[15] Kagami, O., Baik, S.-H. and Harayama, S. (2004) Effective DNA shuffling methods for enzyme evolution, in *Enzyme Functionality* (ed. A. Svendsen), Marcel Dekker, Inc., New York, pp. 425–441.

[16] Arnold, F.H. and Georgiou, G. (eds) (2003) *Directed Enzyme Evolution: Screening and Selection Methods*, Methods in Molecular Biology, vol. **230**, Humana Press, Inc., Clifton, NJ.

[17] Lutz, S. and Patrick, W.M. (2004) Novel methods for directed evolution of enzymes: quality, not quantity. *Current Opinion in Biotechnology*, **15**, 291–297.

[18] Morley, K.L. and Kazlauskas, R.J. (2005) Improving enzyme properties: when are closer mutations better? *Trends in Biotechnology*, **23**, 231–237.

[19] Macauley-Patrick, S., Fazenda, M.L., McNeil, B. and Harvey, L.M. (2005) Heterologous protein production using the *Pichia pastoris* expression system. *Yeast*, **22**, 249–270.

[20] Sorensen, H.P. and Mortensen, K.K. (2005) Advanced genetic strategies for recombinant protein expression in *Escherichia coli*. *Journal of Biotechnology*, **115**, 113–128.

[21] Nohr, J., Kristiansen, K. and Krogsdam, A.-M. (2003) *Expression of Recombinant Proteins: An Introduction*, in *Methods in Molecular Biology*, vol. **232**, Humana Press, Inc., Clifton, NJ, pp. 93–101.

[22] Gellissen, G. (ed.) (2005) *Production of Recombinant Proteins*, Wiley–VCH.

[23] Scopes, R.K. (ed.) (1994) *Protein Purification*, 3rd edn, Springer-Verlag.

[24] Goldberg, K., Schroer, K., Luetz, S. and Liese, A. (2007) Biocatalytic ketone reduction – a powerful tool for the production of chiral alcohols – part I: processes with isolated enzymes. *Applied Microbiology and Biotechnology*, **76**, 237–248.

[25] Yang, W., Xu, J.-H., Xie, Y. *et al.* (2006) Asymmetric reduction of ketones by employing *Rhodotorula* sp. AS2.2241 and synthesis of the β -blocker (*R*)-nifenalol. *Tetrahedron: Asymmetry*, **17**, 1769–1774.

[26] Husain, M. and Husain, Q. (2008) Applications of redox mediators in the treatment of organic pollutants by using oxidoreductive enzymes: a review. *Critical Reviews in Environmental Science and Technology*, **38**, 1–42.

[27] Goldberg, K., Schroer, K., Luetz, S. and Liese, A. (2007) Biocatalytic ketone reduction – a powerful tool for the production of chiral alcohols – part II: whole-cell reductions. *Applied Microbiology and Biotechnology*, **76**, 249–255.

[28] Kroutil, W., Mang, H., Edeger, K. and Faber, K. (2004) Biocatalytic oxidation of primary and secondary alcohols. *Advanced Synthesis & Catalysis*, **346**, 125–142.

[29] Steinbacher, S., Stumpf, M., Weinkauf, S. *et al.* (2002) Enoate reductase family. In *Flavins and Flavoproteins* (2002), Proceedings of the 14th International Symposium, Cambridge, United Kingdom, July 14–18, pp. 941–949.

[30] Stuermer, R., Hauer, B., Hall, M. and Faber, K. (2007) Asymmetric bioreduction of activated C:C bonds using enoate reductases from the old yellow enzyme family. *Current Opinion in Chemical Biology*, **11**, 203–213.

[31] Holland H.L. (1999) C–H activation. *Current Opinion in Chemical Biology*, **3**, 22–27.

[32] Que, L. Jr. (2000) One motif—many different reactions. *Nature Structural Biology*, **7**, 182–184.

[33] Emerson, J.P., Farquhar, E.R. and Que, L. Jr. (2007) Structural ‘snapshots’ along reaction pathways of non-heme iron enzymes. *Angewandte Chemie, International Edition*, **46**, 8553–8556.

[34] Yun, C.-H., Yim, S.-K., Kim, D.-H. and Ahn, T. (2006) Functional expression of human cytochrome P450 enzymes in *Escherichia coli*. *Current Drug Metabolism*, **7**, 411–429.

[35] Celik, A., Flitsch, S.L. and Turner, N.J. (2005) Efficient terpene hydroxylation catalysts based upon P450 enzymes derived from actinomycetes. *Organic & Biomolecular Chemistry*, **3**, 2930–2934.

[36] Fujita, K.-I. and Kamataki, T. (2002) Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH-cytochrome P450 reductase: prediction of metabolism and toxicity of drugs in humans. *Drug Metabolism and Pharmacokinetics*, **17**, 1–22.

[37] Uno, T., Nakao, A., Masuda, S. *et al.* (2006) Modification of small molecules by using cytochrome P450 expressed in *Escherichia coli*. *Journal of Industrial Microbiology & Biotechnology*, **33**, 1043–1050.

[38] Kroutil, W., Mang, H., Edeger, K. and Faber, K. (2004) Biocatalytic oxidation of primary and secondary alcohols. *Advanced Synthesis & Catalysis*, **346**, 125–142.

[39] Kumar, A.K. and Goswami, P. (2006) Functional characterization of alcohol oxidases from *Aspergillus terreus* MTCC 6324. *Applied Microbiology and Biotechnology*, **72**, 906–911.

[40] Overhage, J., Steinbuechel, A. and Priefert, H. (2006) Harnessing eugenol as a substrate for production of aromatic compounds with recombinant strains of *Amycolatopsis* sp. HR167. *Journal of Biotechnology*, **125**, 369–376.